Amgen Inc.(AMGN) Stock Research - Grey Stern Research
Loading...

Amgen Inc. (AMGN) Stock Analysis

$313.71 (0.34%)

AMGN Financial Performance


Use the table below to view Amgen Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $312.64 -
52 Week Low $253.30 -
52 Week High $346.85 -
Market Cap $168.0 Billion 5/9
Gross Margin 66% 7/9
Profit Margin 7% 6/9
EBITDA margin 25% 5/9
Q4 - 2024 Revenue $9.1 Billion 7/9
Q4 - 2024 Earnings $627.0 Million 5/9
Q4 - 2024 Free Cash Flow $4.4 Million 3/9
Trailing 4 Quarters Revenue $33.4 Billion 7/9
Trailing 4 Quarters Earnings $4.1 Billion 6/9
Quarterly Earnings Growth -18% 7/9
Annual Earnings Growth -31% 6/9
Quarterly Revenue Growth 11% 3/9
Annual Revenue Growth 15% 3/9
Cash On Hand $12.0 Billion 2/9
Short Term Debt $3.6 Billion 3/9
Long Term Debt $56.5 Billion 2/9

Amgen Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Amgen Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 41.06 4/9
PS 5.03 3/9
PB 28.58 3/9
PC 14.03 3/9
Liabilities to Equity 14.63 2/9
ROA 0.04 3/9
ROE 0.70 3/9
Current Ratio 1.07 4/9
Quick Ratio 0.14 3/9
Long Term Debt to Equity 9.62 2/9
Debt to Equity 10.23 2/9
Burn Rate 4.75 1/9
Cash to Cap 0.07 3/9
CCR 7.02 2/9
EV to EBITDA 93.50 4/9
EV to Revenue 6.47 3/9

Company Details

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

CEO: Mr. Robert Bradway

Website: https://www.amgen.com

Address: 1 Amgen Center Dr Thousand Oaks, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Drug Manufacturers—General

Amgen Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Amgen Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Pfizer Inc. PFE $145.8 Billion
Bristol-Myers Squibb Company BMY $119.7 Billion
Gilead Sciences, Inc. GILD $138.8 Billion
AbbVie Inc. ABBV $373.8 Billion
Merck & Co., Inc. MRK $238.9 Billion
Johnson & Johnson JNJ $392.0 Billion
Biogen Inc. BIIB $20.4 Billion
Eli Lilly and Company LLY $771.2 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
AMGN Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 9.1 Billion $627.0 Million
Q3 2024 $ 8.5 Billion $2.8 Billion
Q2 2024 $ 8.4 Billion $746.0 Million
Q1 2024 $ 7.4 Billion -$113.0 Million
Q4 2023 $ 8.2 Billion $767.0 Million
Q3 2023 $ 6.9 Billion $1.7 Billion
Q2 2023 $ 7.0 Billion $1.4 Billion
Q1 2023 $ 6.1 Billion $2.8 Billion

View All

AMGN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $12.0 Billion $91.8 Billion $60.1 Billion $5.9 Billion
Q3 2024 $9.0 Billion $90.9 Billion $60.4 Billion $7.5 Billion
Q2 2024 $9.3 Billion $90.9 Billion $62.6 Billion $5.9 Billion
Q1 2024 $9.7 Billion $93.0 Billion $64.0 Billion $5.0 Billion
Q4 2023 $0 $97.2 Billion $64.6 Billion $6.2 Billion
Q3 2023 $34.7 Billion $90.5 Billion $60.5 Billion $7.7 Billion
Q2 2023 $34.2 Billion $90.3 Billion $61.5 Billion $6.8 Billion
Q1 2023 $31.6 Billion $88.7 Billion $61.6 Billion $5.3 Billion

View All

AMGN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 $4.4 Billion -$371.0 Million $3.0 Billion
Q3 2024 $3.3 Billion -$257.0 Million -$290.0 Million
Q2 2024 $2.2 Billion -$238.0 Million -$407.0 Million
Q1 2024 $459.0 Million -$230.0 Million -$1.2 Billion
Q4 2023 $289.0 Million -$249.0 Million -$23.8 Billion
Q3 2023 $2.8 Billion $0 $493.0 Million
Q2 2023 $0 $0 $0
Q1 2023 $720.0 Million -$344.0 Million $23.9 Billion

View All